Skip to main content
. 2015 Jul 23;26(10):2149–2154. doi: 10.1093/annonc/mdv307

Figure 1.

Figure 1.

CT and PET of sacral GCTB pre- and post-denosumab treatment. A 30-year-old female with recurrent unresectable GCTB of the sacrum. SLD, sum of the lesion diameters; SUVmax, maximum standardized uptake value.